Over the last three decades, HIV/AIDS has remained the major health priority for many countries across the globe. Although this sector has seen a significant number of developments in recent years, AIDS-related illnesses remain one of the leading causes of death globally and is projected to continue as a significant global cause of premature mortality in the coming decades (World Health Organization, 2008). In 2008 Sub-Saharan Africa and Asia collectively accounted for the majority of all HIV patients. However, the number of HIV patients has also continued to increase in North America, Western Europe and Japan. Approximately 1.4m individuals in the seven major markets have HIV/AIDS, according to UN AIDS it is estimated that a high proportion of these patients are unaware of their HIV status. This represents a considerable untapped patient population, which currently escapes diagnosis and subsequent treatment. HIV is likely to remain one of the most common chronic infectious diseases in the world. As antiretroviral drugs improve in tolerability, safety and long-term efficacy, there will be continued requirement to initiate treatment in larger numbers of infected individuals. HIV has a tendency of developing resistance towards drugs because of its high mutation rate. This has resulted in a standard regimen of care for controlling HIV which involves simultaneous use of a combination of antiviral drugs. The current market for HIV treatment is dominated by once-daily regimens. There is a strong trend towards regimen simplification and reduced pill burden, which has resulted in the rapid penetration of several once daily (OD) treatment options. The global HIV pipeline represents a key development opportunity for drug development companies, with 297 compounds estimated to be in development. The potential for market success is largely attributable to a large patient population, which requires long term treatment, and significant unmet need.
This report provides comprehensive coverage of the HIV market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the HIV market. It also identifies products in late stage development and forecasts their expected sales performance. rbhc0283
Scope of this research
- Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
- Compare the franchises of the leading companies in HIV, and understand how the market share of these companies will change.
- Evaluate pipeline compounds for the treatment of HIV and determine which products will provide the greatest revenue growth.
- Understand the market dynamics and interactions between the key drug classes used in the treatment of HIV.
- Forecast the performance of the leading marketed and pipeline products through to 2015.
Research and analysis highlights
The global market for HIV treatments was valued at over $13bn in 2009 with the US being the largest market and the five major EU markets collectively being the second largest market. This is despite the majority of HIV infected individuals being found in sub-saharan Africa where financial constraints restrict patient access to medicine.
In September 2010, Gilead released the new 48 weeks data from its ongoing trial on fixed dose Quad regimen combining elvitegravir, cobicistat and Truvada, which was comparable to Atripla in reducing viral loads. This product may be a major driver of growth for Gilead Sciences over the next five years.
Gilead Sciences is the leading player in the HIV market with a market share of approximately 40%. The potential launch of its Quad Pill product is likely to reinforce the company’s position. The second largest player in the market was GSK which has since merged its HIV franchise with that of Pfizer to form ViiV Healthcare.
Key reasons to purchase this research
- Who were the leading players in the HIV market in 2009 and which products were driving their performance?
- Which products are leading each of the leading drug classes for the treatment of HIV and how will this change through to 2015?
- Which pipeline products are best positioned to drive continued market growth for their developers?
- Which of the seven major markets have the greatest prevalence of HIV?